




Most cancer researchers take care
when making media statements
about progress in their field. Most
science journalists, too, deal with the
subject cautiously. Both understand
the dangers of raising false hopes.
Yet a recent episode in the UK
shows how the well-intentioned
handling of a story, from laboratory
bench to the popular media, can still
have unfortunate consequences.
The chain began with a paper in the
Proceedings of the National Academy of
Sciences (Henderson et al., 1998,
95:5275-5280) showing that mice
lacking the glutathione S-transferase
gene developed significantly more
benign skin tumours, as compared to
mice with the gene, when exposed
to a polycyclic hydrocarbon. 
Publication was heralded by a
press release from the Imperial
Cancer Research Fund (ICRF),
which had partly sponsored the
research. “This is a very exciting
finding,” said co-author Roland
Wolf. “We’ve shown for the first
time that a single gene could be
profoundly important in protecting
us against cancer. And that’s good
news because it’s easier to
manipulate one gene than many”.
Ken Brown of the Cancer Research
Campaign, which had also funded
the work, added: “It’s a very
important discovery.”
An avalanche of publicity
followed. The Daily Mail and the
Express carried front page pieces
with headlines 10 centimetres deep,
while on television both the BBC
and ITN main evening news
bulletins gave the story considerable
prominence. Virtually all national
newspapers allocated a substantial
amount of space to the
announcement, and all of the
broadcasting channels gave generous
amounts of time. There was much
talk of a “lung disease
breakthrough”, “a cancer prevention
pill” and “new drug therapies that
prevent many forms of the disease”.
Soon, however, all concerned
seemed to realize that the episode
had been over-blown. The
Independent on Sunday, for example,
quoted Ken Brown as being
surprised at the coverage. He said
not only that the relevance of the
study to human cancer was
uncertain, but also that both Nature
and Science had rejected the paper
because “it wasn’t a major enough
discovery for them.”
Even if the wording of an article is
judicious, newspaper readers are
impressed by huge headlines
In reality, the perplexities and
irritations arose largely from the size
and impact of the media blitz, rather
than from its detailed content.
Although there was some
sensationalism, most of the accounts
were unusually guarded. Jenny
Hope, writing in the Daily Mail,
cautiously noted that the discovery
“could be the starting point for
research leading to new anti-cancer
drugs and could eventually mean
that genetic engineering could be
used to enhance the body’s natural
defence system.”
Such caution may be contrasted
with the self-confessed excitement
of some of the scientists involved.
Much more sober was Paul Nurse,
director-general of the ICRF, who
was cited in the Guardian’s account.
“We are talking about mice, and we
are talking about the induction of
precancerous growths on skin which
have been induced by chemicals,”
Nurse said. “It would need to be
shown to be relevant to humans.”
So why, for at least a day, did
banner headlines and TV interviews
with cancer researchers dominate
public attention ahead of issues
such as the middle east peace
process, political change in
Northern Ireland and famine and
conflict in the Sudan?
The answer probably rests in one
simple observation about the way in
which target audiences respond to an
announcement of this sort. Science
correspondents and editors alike
know that medical scientists as a
group tend to be exceedingly
cautious. They also recognize that
cancer research is a time-consuming,
incremental process, with countless
disappointments along the way. The
antennae of even the most
level-headed of them twitch,
therefore, when researchers
announce that a new development is
“very exciting”, “good news” and
“very important”. Likewise, even if
the actual wording of an article is
judicious, newspaper readers are
impressed by huge headlines on
page one. TV viewers are similarly
affected when a prime-time
programme includes a substantial
item about an advance in dealing
with a deadly and feared disease.
The crucial error in the press
release was the failure to point out
that although the finding is
scientifically exciting, an enormous
amount of work remains to be done
to determine whether it has any real
implications for human cancer.
There’s another necessary caution.
Media coverage like that surrounding
the “cancer gene” story
re-emphasises the erroneous belief
that cancer is a single disease, for
which scientists are seeking the cure.
It overshadows the reality that many
cancers can already be cured if
detected sufficiently early, while
others may be avoided by lifestyle
changes such as not smoking. 
Reporting that obscures these
facts is not only regrettable in terms
of public understanding. It could also,
for particular individuals, mean the
difference between life and death.
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